Compare Incyte Corporation (INCY) vs Western Digital Corp (WDC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Western Digital Corp — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while Western Digital Corp trades at $523.9 (market cap $168.00B). The key difference: Western Digital Corp is far larger — about 7.3× Incyte Corporation's market cap, and Western Digital Corp pays a 0.12% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | WDC | |
|---|---|---|
Market Cap | $23.11B | $168.00B |
Sector | Health | Technology |
52-Week High | $118.52 | $746.23 |
52-Week Low | $67.38 | $67.06 |
Enterprise Value | $19.13B | $166.35B |
Dividend Yield | — | 0.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Western Digital (WDC) trades at $489.59, up 2.59% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows mixed technical signals with bearish moving averages but positive analyst sentiment, including a $619.07 consensus price target representing 26% upside. Recent volatility reflects sector rotation in memory stocks amid AI infrastructure expansion driving storage demand.
WDC presents compelling growth potential from AI-driven storage demand but faces near-term volatility from competitive pressures and sector rotation. The company's improving profitability (55.07% net margin) and cash flow generation support the bullish analyst outlook, though investors should monitor execution against Q2 2026 earnings expectations of $3.34 EPS.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Western Digital Corp
Western Digital is a vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
Read more on WDC →
